Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3656404 | 0.99 | AOC3 (0.45) | AOC3MEN1LMNAKMT2AGAA | |
| SCHEMBL121248 | 0.88 | TSHR (0.39) | MEN1LMNAKMT2AGAATSHR | |
| Hydrochloric Acid SCHEMBL119950 | 0.87 | TSHR (0.38) | MEN1LMNAKMT2AGAATSHR | |
| SCHEMBL1120383 | 0.85 | AOC3 (0.45) | AOC3LMNAGAATSHRSMN1; SMN2 | |
| SCHEMBL1120478 | 0.81 | SMN1; SMN2 (0.38) | AOC3MEN1LMNAKMT2AGAA | |
| SCHEMBL989795 | 0.81 | AOC3 (0.62) | AOC3CNR2TAAR1 | |
| SCHEMBL934512 | 0.79 | ALDH1A1 (0.43) | AOC3LMNAGAASMN1; SMN2KDM4E | |
| SCHEMBL1120437 | 0.79 | DAO (0.40) | AOC3NR3C1CNR2 | |
| SCHEMBL3664012 | 0.78 | LOXL2 (0.44) | LMNAKMT2AGAATSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3664721 | 0.77 | LOXL2 (0.43) | LMNAKMT2AGAATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255094-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999977-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8546381-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190303-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424364-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2274307-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| CN-101952284-A | Novel tetracyclic compounds | MEDIVATION TECHNOLOGIES INC | 2011-01-19 | — | — | CN | disclosed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| WO-2009120720-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES,INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | AOC3 341/4885MEN1 1883/4885LMNA 4766/4885 |
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AOC3 358/4885MEN1 2574/4885LMNA 4473/4885 |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | AOC3 341/4885MEN1 1883/4885LMNA 4766/4885 |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AOC3 358/4885MEN1 2574/4885LMNA 4473/4885 |
| US-20130190303-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | AOC3 341/4885MEN1 1883/4885LMNA 4766/4885 |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | AOC3 341/4885MEN1 1883/4885LMNA 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.